Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
about
Onto better TRAILs for cancer treatmentPlant sterols as anticancer nutrients: evidence for their role in breast cancerLB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialTargeting the apoptosis pathway in hematologic malignanciesGetting TRAIL back on track for cancer therapyCaspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcomaGeneral Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMACTrailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsMetformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer CellsGene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesA set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein.Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells.Developing pharmacogenetic evidence throughout clinical development.Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesotheliomaSulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.H-Ras regulation of TRAIL death receptor mediated apoptosisMulti-layered nanoparticles for combination gene and drug delivery to tumors.Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cellsInduction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide.New therapeutic targets in soft tissue sarcoma.A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 ExpressionTRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Epidemiology and therapies for metastatic sarcomaDrug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy.Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator.Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer CellsEvaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.
P2860
Q26768160-C317EBF7-65FC-42E7-BCAB-334DD9F2F7A1Q26861053-5B9A6C6B-81A6-4E99-89F4-328572AD698EQ26865711-31282EB2-1065-4C75-8CFD-98A3C2F07E0CQ27024422-21055296-3403-4BA6-A554-AA767AB27B94Q27027460-3ED00D63-1584-4CBD-8737-C0B332DD5315Q27853200-55C5F4CD-7912-4086-9AAD-614D848E8BC0Q28385542-7C3EDAC5-B54A-4D43-8AFA-6C7BCC247985Q28391040-470979FA-63B9-4835-AC70-D9CD1D8DCAF8Q28547140-D09CAB2F-1938-4C42-BA1A-7EA4FC5B5596Q28548165-70B0FFDC-A3D1-40A5-8A9F-DB8FFBE66158Q30361915-6B4C94C6-37CE-48C9-88A3-7EEF90B01806Q30854013-9533C4EF-3265-4F1D-AF75-B14FBF42FAA0Q33276109-3BD4B89A-C996-4B28-AFA6-D274829C1224Q33435243-87423D48-768F-44B9-99B1-AE64F52B08FAQ33576675-23FB5A78-580B-4103-8549-705FB5BDB29DQ33658976-E0CB191C-2599-43A1-9F95-343FE5325ACDQ33685260-2B21E295-E1B3-42E6-9827-13B14DF0E3D4Q33730146-832E62B1-32D9-467F-8066-EF70EECB6676Q33739941-FB92383D-625A-4B4A-BB50-AFBD7D9A492BQ33834736-4CD661C9-00BA-4025-BBDC-53AB1411EB13Q34028460-4AAB8AF8-3E12-40B9-BCF9-BA95EFF8083DQ34038664-007DB2F9-848B-4FD3-9AA6-72C5115E98CFQ34104161-F7B43F08-B7A8-44D5-ABA9-87DEED19BA12Q34135640-7595482E-B4BA-448C-85DF-F7B27B499FD2Q34193833-020A9051-F3BD-4FB7-BFFD-6B87B41D9517Q34217464-0E6C3E99-3209-4DA1-9B2B-E925A19421C6Q34267924-73B253F3-3279-4860-8EAA-B004E638FE72Q34344012-62C3086B-556E-4807-A894-A16213C5DECBQ34464915-AC11DB98-B995-468B-8B1B-7DE4DF8E2AD8Q34557885-6D342895-CC3E-49DA-9A7F-3E99787F8D85Q34652142-A99CBB2B-A4BD-41D8-A559-8A4D44C5BA4EQ34806765-1476FC0F-73E1-42E8-AEBB-3947253BE7BDQ34988055-A92E238B-C16A-4803-9352-B1C7EA0630F9Q35063836-C1425413-F46E-4D6B-BB6F-450F07B19F72Q35154965-2CF87CF0-6FE5-4CE1-8C5E-C50B9D7C36F3Q35183874-4A3914F5-8434-4323-B325-9B5F82FB026FQ35344969-8AAFEEAC-8DB7-4330-BEB0-6067DD85B22EQ35590091-438EFE68-4EFF-44F9-B9D0-85E9E0296CD2Q35639178-B14EE922-C583-4F65-B550-465E916FC2EFQ35653933-E8A4F86C-5573-43E4-B2DA-23398A8C1986
P2860
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Phase I dose-escalation study ...... patients with advanced cancer.
@en
type
label
Phase I dose-escalation study ...... patients with advanced cancer.
@en
prefLabel
Phase I dose-escalation study ...... patients with advanced cancer.
@en
P2093
P356
P1476
Phase I dose-escalation study ...... patients with advanced cancer.
@en
P2093
Adrian M Jubb
Avi Ashkenazi
Bert L Lum
David S Mendelson
Meredith A Goldwasser
Michael S Gordon
Peter J O'Dwyer
S Gail Eckhardt
Scot Ebbinghaus
Tanyifor M Tohnya
P304
P356
10.1200/JCO.2009.25.1991
P407
P577
2010-05-10T00:00:00Z